Opus Genetics, Inc. (IRD) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-106.9%

-$0.25

vs $3.70 price

Levered DCF

-$0.23

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-4.73

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-2.51×	-0.55×	-2.8×	1.43×	-0.34×	-0.24×	-1.48×
P/B	81.49×	4.73×	0.56×	0.56×	0.86×	-0.45×	-1.21×
P/S	88.1×	2.89×	1.46×	0.65×	32.53×	0×	0×
EV / EBITDA	-25.08×	-0.03×	2.27×	-0.93×	0.09×	0.58×	-2.79×
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%
Operating margin	-271.9%	-564.7%	-55.5%	45.7%	-3854.8%	0.0%	0.0%
Net margin	-349.3%	-523.4%	-52.4%	44.9%	-9625.3%	0.0%	0.0%
Current ratio	6.43×	3.24×	13.35×	17.79×	6.76×	5.55×	0.19×
Debt / equity	0×	0×	0×	0×	0.02×	0×	-0.75×
Interest coverage	-26.33×	0×	-7.95×	2,025.11×	-11,352.5×	-2.92×	-2.98×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-323.1%	-855.6%	-20.0%	38.7%	-255.1%	182.8%	81.6%
Return on invested capital	-90.9%	-242.8%	-21.2%	38.7%	-99.8%	-137.7%	221.5%
Return on assets	-98.7%	-156.1%	-18.5%	36.5%	-217.4%	-139.2%	-345.8%
Free cash flow yield	-2.8%	-80.4%	-4.0%	55.7%	-101.1%	-113.0%	-39.5%
Earnings yield	-4.0%	-181.0%	-35.9%	69.6%	-295.9%	-409.5%	-67.4%
Enterprise value	$1.2B	$1.5M	-$22.7M	-$16.9M	-$4.8M	-$10.4M	$13.3M
Net debt / EBITDA	0.94×	0.53×	5.07×	-2.34×	0.42×	0.92×	-0.87×
Cash conversion cycle (days)	81	192	45	44	0	0	0